Novo Nordisk A/S is reorganising its research organisation to accelerate the development of novel therapies for serious chronic diseases. The move represents a shift away from traditional insulin products and into, among other things, cardio-metabolic and stem cell research.
The Danish company will also increase investment in digital technologies and artificial intelligence to help identify lead molecules and develop them faster. As a consequence, the size of company’s R&D workforce will be reduced with the loss of about 400 jobs in Denmark and China.